Allison Bratzel
Stock Analyst at Piper Sandler
(4.78)
# 132
Out of 4,667 analysts
32
Total ratings
73.68%
Success rate
23.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintains: Neutral | $12 → $22 | $17.86 | +23.18% | 2 | Nov 14, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $15 → $23 | $24.31 | -5.39% | 2 | Nov 14, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $65 → $62 | $35.40 | +75.14% | 1 | Nov 14, 2024 | |
| ARGX argenx SE | Maintains: Overweight | $553 → $620 | $591.82 | +4.76% | 12 | Nov 1, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $28 → $42 | $27.86 | +50.75% | 3 | Oct 15, 2024 | |
| ROIV Roivant Sciences | Maintains: Overweight | $20 → $22 | $11.49 | +91.47% | 2 | Jul 10, 2024 | |
| HUMA Humacyte | Maintains: Neutral | $4 | $4.41 | -9.30% | 2 | Mar 26, 2024 | |
| SLDB Solid Biosciences | Upgrades: Overweight | $8 → $20 | $4.96 | +303.23% | 4 | Mar 14, 2024 | |
| ABCL AbCellera Biologics | Assumes: Overweight | $20 | $2.67 | +649.06% | 1 | Oct 13, 2023 | |
| REPL Replimune Group | Assumes: Overweight | $44 | $11.23 | +291.81% | 1 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 | $71.05 | +40.75% | 2 | Feb 8, 2023 |
Travere Therapeutics
Nov 14, 2024
Maintains: Neutral
Price Target: $12 → $22
Current: $17.86
Upside: +23.18%
Rigel Pharmaceuticals
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $24.31
Upside: -5.39%
Ionis Pharmaceuticals
Nov 14, 2024
Maintains: Overweight
Price Target: $65 → $62
Current: $35.40
Upside: +75.14%
argenx SE
Nov 1, 2024
Maintains: Overweight
Price Target: $553 → $620
Current: $591.82
Upside: +4.76%
Scholar Rock Holding
Oct 15, 2024
Maintains: Overweight
Price Target: $28 → $42
Current: $27.86
Upside: +50.75%
Roivant Sciences
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $11.49
Upside: +91.47%
Humacyte
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $4.41
Upside: -9.30%
Solid Biosciences
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $4.96
Upside: +303.23%
AbCellera Biologics
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $2.67
Upside: +649.06%
Replimune Group
Apr 17, 2023
Assumes: Overweight
Price Target: $44
Current: $11.23
Upside: +291.81%
Feb 8, 2023
Maintains: Overweight
Price Target: $100
Current: $71.05
Upside: +40.75%